Diary

  • Mon
    18
    Jan
    2021
    Tue
    19
    Jan
    2021

    10am - 12.30pmOnline, live event


    Format:
    This is a live, virtual event. Each morning’s content is split over three pre-recorded videos of 30-40 minutes each. Elaine will be online throughout both mornings to interact with learners and answer questions in the live Q&A sessions that follow each video. The presentations will be available online for 30 days after the live event.

    Description:

    The aim of this course, spread over two mornings, is to provide learners with a good, general understanding of the concepts that underlie precision cancer medicine.

    The fundamental idea of precision medicine is to offer each cancer patient a treatment approach that is tailored to the unique biology and genetics of their disease. Elaine will explain how far we are able to do this by exploring the features of cancer we can target now, and where we might get to in the future. She will also look at when precision medicine falls down, and why expectations and realities don’t always align.

    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine's other courses
    Cost:
    £50 per morning
    To book, contact: conferenceteam@rmh.nhs.uk
    View the programme for morning 1
    View the programme for morning 2

  • Thu
    09
    Dec
    2021
    Fri
    10
    Dec
    2021

    10am - 12.30pmOnline, live event


    Description:
    Over the course the first morning, Elaine guides you through the scientific concepts that underpin many of the most used targeted cancer treatments for solid tumours.

    Elaine begins by describing what we can and can't target, and the mechanisms of action of monoclonal antibodies and small molecules that block kinases. She then looks at the many treatments that block growth factor controlled signalling pathways. Finally, she turns her attention to other targets and to various biomarker tests to select the right approach for each patient.

    On the second morning the focus is on cancer’s relationship with the immune system, and how this knowledge is being used to improve the outlook of people with many different cancer types. Checkpoint inhibitors (e.g. nivolumab, pembrolizumab) will take centre-stage.

    Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine's other courses
    Cost:
    £50 per morning
    To book, contact: conferenceteam@rmh.nhs.uk or book online
    View a PDF of the programme